Abata Therapeutics is bringing an entirely new approach to the treatment of autoimmune disease by engineering Tregs as targeted therapies that stop immune-mediated destruction, restore homeostasis – a state of harmony – and promote repair in the affected tissues. In addition to their lead program in progressive MS, Abata has early programs in Type 1 Diabetes (T1D) and inclusion body myositis (IBM). They bring together industry experts and deeply engaged pioneers in Treg biology, T cell receptor and antigen discovery, disease pathogenesis, and molecular and imaging biomarkers.

Biotechnology

Abata Therapeutics

Samantha Singer

Stephen Fair

Leonard Dragone

Sandy Lazzari

Reut Brauner

Alec Silverman

Bethan Chilton

Amina Abbadi

Ellen Cahir-McFarland

Christina Strange

Cristina Musselli

Cristin Berkey

John Trzupek

The Research and Development team at Abata Therapeutics is focused on pioneering innovative therapies for autoimmune diseases using engineered Tregs. They conduct cutting-edge research in Treg biology, T cell receptor and antigen discovery, and disease pathogenesis, aiming to develop targeted treatments that halt immune-mediated tissue destruction, restore balance, and promote tissue repair. Their efforts span from preclinical research to clinical translation, with programs targeting progressive MS, Type 1 Diabetes, and inclusion body myositis.

Research and Development

Advisory Team

Leadership Team

Research and Development

About

Team members

Other teams at Abata Therapeutics

Advisory Team

Leadership Team